Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Abigail Lewis
Advertisement
Articles by Abigail Lewis
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
3
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
4
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
5
